Monopar Therapeutics Presents Positive ALXN1840 Phase 3 Findings at EAN 2026
WILMETTE, Ill., June 26, 2026 Monopar Therapeutics announced new analyses from its Phase 3 FoCus clinical trial demonstrating that...
FDA NDA
Advertisement
CeleCor Submits FDA NDA for Zalunfiban After Phase 3 Success
DEL MAR, Calif., June 24, 2026 CeleCor Therapeutics announced the completion of its New Drug Application (NDA) submission to...
Abivax’s Obefazimod Delivers Landmark Phase 3 Success in Ulcerative Colitis
PARIS, France, June 1, 2026 Abivax announced positive topline results from its pivotal Phase 3 ABTECT maintenance trial evaluating...
Foresee Pharmaceuticals Reports Positive CPP Phase 3 Data
TAIPEI, Taiwan, May 27, 2026 Foresee Pharmaceuticals has announced the successful completion of its Casppian Phase 3 clinical trial...
Mirum Volixibat Achieves Phase 2b Success in PSC Trial
FOSTER CITY, Calif., May 4, 2026 Mirum Pharmaceuticals, Inc. has announced that its Phase 2b VISTAS clinical study of...
Advertisements
Abbisko Pimicotinib NDA Progress Advances TGCT Therapy
Shanghai, China – April 22, 2026 In a major milestone for rare tumor therapeutics, Abbisko Therapeutics has announced significant...
Cristcot NDA Accepted for ngHCA in Ulcerative Colitis
Austin, Texas, USA, April 21, 2026 In a significant regulatory milestone for gastrointestinal therapeutics, Cristcot HD LLC has announced...
Cogent Biosciences Files NDA for Bezuclastinib in GIST
WALTHAM, Mass. and BOULDER, Colo., April 1, 2026 Cogent Biosciences, Inc. has announced the successful submission of a New...
Merck’s Two-Drug HIV Therapy Shows Strong Phase 3 Efficacy
RAHWAY, N.J. – October 15, 2025 — Merck (NYSE: MRK) announced new Phase 3 trial results for its investigational,...
Advertisement
